Company intelligence / Profile preview

Kalaris Therapeutics, Inc.

Palo Alto, California, United Stateskalaristx.com ↗

Ownership: Private
Employees: ~14
Development stage: Phase 1

Overview

Currently developing TH103, a novel anti-VEGF agent in Phase 1 clinical trial for nAMD. Initial data from Part 1 of the trial is expected in the second half of 2025. TH103 has demonstrated potent anti-VEGF activity and sustained ocular residence time in preclinical studies.

Therapeutic areas: Ophthalmology
Modalities: Recombinant fusion protein
Industry: Biotech

Drug pipeline

14 assets

posoleucel

13 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kalaris Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kalaris Therapeutics, Inc..

Explore the full profile